Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
REPL Replimune Group, Inc. daily Stock Chart
REPL [NASD]
Replimune Group, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.66 Insider Own14.00% Shs Outstand39.86M Perf Week71.81%
Market Cap1.71B Forward P/E- EPS next Y-2.10 Insider Trans-3.77% Shs Float35.71M Perf Month87.12%
Income-60.60M PEG- EPS next Q-0.44 Inst Own85.10% Short Float2.61% Perf Quarter107.94%
Sales- P/S- EPS this Y-15.60% Inst Trans-2.43% Short Ratio1.93 Perf Half Y287.40%
Book/sh6.97 P/B6.09 EPS next Y-11.00% ROA-25.10% Target Price38.63 Perf Year187.40%
Cash/sh6.50 P/C6.53 EPS next 5Y- ROE-31.10% 52W Range8.58 - 46.30 Perf YTD195.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.38% Beta-
Dividend %- Quick Ratio22.50 Sales past 5Y- Gross Margin- 52W Low394.41% ATR3.28
Employees122 Current Ratio22.50 Sales Q/Q- Oper. Margin- RSI (14)84.15 Volatility27.21% 11.06%
OptionableNo Debt/Eq0.13 EPS Q/Q-46.10% Profit Margin- Rel Volume0.74 Prev Close42.16
ShortableYes LT Debt/Eq0.12 Earnings- Payout- Avg Volume482.62K Price42.42
Recom1.90 SMA2058.31% SMA5068.18% SMA200120.38% Volume356,283 Change0.62%
Oct-15-20Upgrade H.C. Wainwright Neutral → Buy $25 → $54
Jul-01-20Downgrade H.C. Wainwright Buy → Neutral $25
May-05-20Initiated Barclays Overweight $21
Sep-04-19Initiated ROTH Capital Buy $20
Jul-23-19Initiated Chardan Capital Markets Buy $28
Jul-12-19Upgrade JP Morgan Neutral → Overweight $27 → $26
Jul-08-19Initiated H.C. Wainwright Buy $26
Apr-25-19Initiated Wedbush Outperform $24
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Aug-14-18Initiated Leerink Partners Outperform $25
Aug-14-18Initiated JP Morgan Overweight $26
Oct-20-20 04:02PM  
Replimune Announces Proposed Public Offering
GlobeNewswire
04:01PM  
Replimune Releases Updated Corporate Presentation
GlobeNewswire
Oct-19-20 04:01PM  
Replimune Appoints Tanya Lewis to the Board of Directors
GlobeNewswire
Oct-15-20 11:33AM  
Why Replimune Stock Is Soaring Today
Motley Fool +13.02%
09:51AM  
Benzinga's Top Upgrades, Downgrades For October 15, 2020
Benzinga
Oct-14-20 12:29PM  
Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire +46.82%
Aug-07-20 07:00AM  
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
GlobeNewswire +11.09%
Aug-04-20 07:00AM  
Replimune to Present at Two Upcoming Investor Conferences
GlobeNewswire
Jul-22-20 07:00AM  
Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer
GlobeNewswire -5.16%
Jun-22-20 02:27PM  
Replimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure
Insider Monkey
Jun-17-20 08:00AM  
Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
GlobeNewswire
Jun-11-20 08:47AM  
Replimune (REPL) Looks Good: Stock Adds 5.8% in Session
Zacks
Jun-08-20 11:21PM  
Replimune Announces Pricing of Upsized Public Offering
GlobeNewswire
04:16PM  
Replimune Announces Proposed Public Offering
GlobeNewswire
Jun-03-20 07:15AM  
Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
GlobeNewswire
07:00AM  
Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimunes Ongoing Registration-Directed Clinical Trials with RP1
GlobeNewswire
Apr-30-20 06:00AM  
Replimune to Provide Data Update on June 3, 2020
GlobeNewswire +20.84%
Apr-02-20 07:00AM  
Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
GlobeNewswire
Feb-13-20 07:00AM  
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
GlobeNewswire
Feb-06-20 08:00AM  
Replimune to Present at Two Upcoming Investor Conferences
GlobeNewswire -5.08%
Jan-13-20 07:00AM  
Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones
GlobeNewswire
Jan-09-20 07:00AM  
Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization
GlobeNewswire
Jan-07-20 08:00AM  
Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference
GlobeNewswire
Dec-23-19 02:56PM  
Replimune Group, Inc. (NASDAQ:REPL): Are Hedge Funds Right About This Stock?
Insider Monkey
Dec-09-19 08:00AM  
Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer
GlobeNewswire
Nov-26-19 08:00AM  
Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference
GlobeNewswire
Nov-22-19 12:13PM  
Largest Insider Trades of the Week
GuruFocus.com
Nov-14-19 06:22AM  
Replimune Announces Pricing of Public Offering
GlobeNewswire
Nov-12-19 04:06PM  
Replimune Announces Proposed Public Offering
GlobeNewswire
Nov-11-19 08:00AM  
Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update
GlobeNewswire
Nov-08-19 07:30AM  
Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)
GlobeNewswire
Oct-31-19 04:00PM  
Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire
02:19PM  
Is Replimune Group, Inc. (REPL) A Good Stock To Buy?
Insider Monkey
Oct-24-19 08:00AM  
Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients
GlobeNewswire
Oct-15-19 07:00AM  
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
GlobeNewswire +15.02%
Oct-02-19 08:00AM  
Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire -5.77%
Oct-01-19 08:00AM  
Replimune to Present at Chardans 3rd Annual Genetic Medicines Conference
GlobeNewswire -5.25%
Sep-13-19 04:39AM  
2 Downtrodden Small Biotechs That Are Showing Signs of Life
TheStreet.com
Aug-14-19 08:00AM  
Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update
GlobeNewswire
Aug-06-19 08:00AM  
Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference
GlobeNewswire -5.53%
Jul-19-19 09:16AM  
Imagine Owning Replimune Group (NASDAQ:REPL) And Wondering If The 17% Share Price Slide Is Justified
Simply Wall St.
Jun-28-19 08:00AM  
Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update
GlobeNewswire +6.15%
Jun-01-19 09:00AM  
Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
GlobeNewswire
May-30-19 08:00AM  
Replimune to Present at Upcoming Investor Conferences
GlobeNewswire
May-16-19 07:00AM  
Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire +5.80%
Apr-25-19 02:23PM  
Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation
Benzinga +6.65%
Apr-01-19 07:00AM  
Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019
GlobeNewswire
Feb-14-19 08:00AM  
Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update
GlobeNewswire
Feb-07-19 08:00AM  
Replimune to Present at Two Upcoming Investor Conferences
GlobeNewswire
Jan-04-19 12:33PM  
How Much Are Replimune Group, Inc. (NASDAQ:REPL) Insiders Spending On Buying Shares?
Simply Wall St.
Jan-03-19 08:00AM  
Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
GlobeNewswire
Dec-20-18 08:00AM  
Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference
GlobeNewswire
Dec-08-18 06:19PM  
RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy?
Insider Monkey
Dec-05-18 08:00AM  
Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
GlobeNewswire
Nov-14-18 08:38AM  
Bain Capital Life Sciences Investors, LLC Buys Replimune Group Inc
GuruFocus.com
08:00AM  
Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update
GlobeNewswire
Sep-26-18 08:00AM  
Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
GlobeNewswire
Sep-06-18 04:01PM  
Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1
GlobeNewswire
Aug-30-18 08:00AM  
Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update
GlobeNewswire -9.20%
Aug-14-18 02:49PM  
BMO Sees A Low-Risk Biotech Buy In Replimune
Benzinga
Jul-24-18 07:44AM  
[$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech
The Wall Street Journal
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Esposito PamelaChief Business OfficerOct 14Option Exercise1.0116,00016,160128,700Oct 16 06:05 PM
Esposito PamelaChief Business OfficerOct 14Sale32.9016,000526,410112,700Oct 16 06:05 PM
Love ColinChief Operating OfficerSep 15Sale23.9715,000359,4871,021,524Sep 17 04:25 PM
Esposito PamelaChief Business OfficerAug 31Option Exercise1.015,0005,050117,700Sep 01 05:13 PM
Esposito PamelaChief Business OfficerAug 31Sale27.055,000135,250112,700Sep 01 05:13 PM
Love ColinChief Operating OfficerAug 17Sale23.4415,000351,5551,036,524Aug 18 05:15 PM
Coffin RobertPresident & Chief R&D OfficerJul 09Sale22.13169,7503,757,2952,024,118Jul 10 09:00 PM
Coffin RobertPres & Chief Res & Dev OfficerFeb 20Sale17.0424,250413,2202,193,868Feb 24 04:02 PM
Coffin RobertPres & Chief Res & Dev OfficerFeb 12Sale17.0448,500826,1982,218,118Feb 14 04:00 PM
Esposito PamelaChief Business OfficerDec 20Option Exercise1.7525,70044,975112,700Dec 23 04:32 PM
Kaufman HowardChief Medical OfficerNov 26Option Exercise3.3058,067191,62158,067Dec 19 04:02 PM
Rhodes Jason PDirectorNov 18Buy13.611,100,00014,971,0001,100,000Nov 20 05:50 PM
Omega Fund IV, L.P.10% OwnerNov 18Buy13.61220,0002,994,2005,328,939Nov 20 12:36 PM
open in yahoo | open in reuters | open in google